Researchers found that ONWARD Medical, a neurotechnology company, is making strides in therapies aimed at restoring movement and independence for individuals with spinal cord injuries and other movement disabilities. During their recent Annual General Meeting, shareholders approved all proposed resolutions, indicating strong support for the company’s ongoing efforts in developing innovative treatments. Their flagship technology, ARC Therapy, has already received multiple Breakthrough Device Designations from the FDA, highlighting its potential impact on patient care.

This development is significant for anyone interested in improving the quality of life for those affected by spinal cord injuries. The ARC-EX® System is already available for commercial use in the U.S. and Europe, which means that people with movement disabilities could soon benefit from therapies designed to enhance their mobility and independence. Moreover, the company is working on the ARC-IM® system, which aims to address additional challenges such as blood pressure instability, further expanding treatment options for this population.

The evidence supporting these technologies comes from extensive research, including clinical studies conducted in leading hospitals and rehabilitation centers. While the ARC-EX® System is cleared for use, the ARC-IM® is still in the investigational phase, meaning it is promising but not yet widely available. As the company continues to innovate, it is essential for those interested in these therapies to stay informed about new developments and potential availability in their area.

To stay updated on ONWARD Medical’s advancements and learn about therapy options, consider visiting their website or signing up for their notifications.

Source: globenewswire.com